WinstonWınston
Back
Stock

Myriad Genetics

MYGN
23
Medical - Diagnostics & Research · Healthcare
Also trades as: 0K3W.L GBP 0.06 (+0.58%)
Price
$5.82
+0.06 (+1.04%)
Market Cap
$556.7M
Exchange
NASDAQ
Winston Score
23
Winston is worried
Weak fundamentals across most pillars.
Data as of Oct 23, 2026 · filings through Jun 30, 2026

§How the score breaks down

Quality
Mixed
8/30
Growth
Weak
3/20
Cash Flow
Weak
0/10
Stability
Mixed
3/10
Valuation
Data not available
0/10
Ownership
Good
8/15
Dividends
Not counted
n/a

22 of 95 counted points = Winston Score 23. Pillars marked n/a do not apply to this company and are left out of the total.

Track this stock — start free trial

Share count rising — dilution

+19.6% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 78.0M (2021) → 93.3M (2025)

§Winston Score History

The full picture

Myriad Genetics is a healthcare company that runs genetic tests for patients and doctors. Its most well-known products are tests that check for gene mutations linked to hereditary cancers, like the BRACAnalysis test for BRCA1 and BRCA2 mutations, which can signal higher risk for breast and ovarian cancer. The company also offers tests for mental health medication matching and prenatal conditions, selling primarily to hospitals, clinics, and physicians across the United States.

Myriad makes money by charging for each genetic test it performs, with payment coming from insurance companies, government programs like Medicare and Medicaid, and patients directly. It operates mainly in the US, with a small international presence, and generates roughly $700–800 million in annual revenue. The company has built a large proprietary database of genetic variants, which gives it some scientific edge, but it faces intense competition from rivals like Labcorp and Invitae, and its ongoing operating losses mean improving reimbursement rates and controlling costs are critical challenges ahead.

Politician Trades

1 trades / 12mo

0 Congressional buys and 1 sell on MYGN in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-10.5% YoY

YoY Growth Rate

Revenue declining

Reported EPS Growth

+87.1% YoY

Quarterly reporting periods ended:

30 Jun 2025: $-3.57

30 Jun 2026: $-0.46

Reported/statutory EPS, not adjusted or underlying earnings. One-off items can affect this figure. Provider rounding can affect the growth rate.

YoY Growth Rate

Reported EPS increased year over year

R&D Spend

$107M/ year

↓ Declining (-6% vs prior year)

13.0% of revenue

Below sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

7.0%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~3 years

$115M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

$115M cash & investments at current burn rate

Revenue declining

Myriad Genetics's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
66.6%
Premium pricing power — 66.6% gross margin
Profit after running costs
Operating Margin
-20.4%
Losing money on operations — -20.4%
Return on the money invested
ROCE
-19.2%
Weak — -19.2% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
-3.2%
Shrinking sales (-3.2% YoY)
Profit growth
EPS YoY
N/A
—
Data not available
How steady the profit is
EPS Consistency
4/8 quarters
Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
—
Data not available
Spare cash per sale
FCF Margin
-1.1%
Burning cash (-1.1%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
0.69
Moderate — manageable debt (0.69)
Covers its interest
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
—
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial